{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:02:16Z","timestamp":1760101336346,"version":"3.40.3"},"publisher-location":"Cham","reference-count":75,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030783105"},{"type":"electronic","value":"9783030783112"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-3-030-78311-2_11","type":"book-chapter","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T13:55:25Z","timestamp":1633874125000},"page":"179-196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Acute Lymphoblastic Leukemia (B-ALL)"],"prefix":"10.1007","author":[{"given":"Geoffrey","family":"Shouse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Budde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Forman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,10]]},"reference":[{"issue":"2","key":"11_CR1","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar Z, Waks T, Gross G, Schindler DG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 90(2):720\u2013724","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6382","key":"11_CR2","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC (2018) CAR T cell immunotherapy for human cancer. Science 359(6382):1361\u20131365","journal-title":"Science"},{"issue":"9","key":"11_CR3","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1172\/JCI80010","volume":"125","author":"M Sadelain","year":"2015","unstructured":"Sadelain M (2015) CAR therapy: the CD19 paradigm. J Clin Invest 125(9):3392\u20133400","journal-title":"J Clin Invest"},{"issue":"22","key":"11_CR4","doi-asserted-by":"publisher","first-page":"10995","DOI":"10.1158\/0008-5472.CAN-06-0160","volume":"66","author":"CM Kowolik","year":"2006","unstructured":"Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N et al (2006) CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 66(22):10995\u201311004","journal-title":"Cancer Res"},{"issue":"1","key":"11_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4049\/jimmunol.172.1.104","volume":"172","author":"HM Finney","year":"2004","unstructured":"Finney HM, Akbar AN, Lawson AD (2004) Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 172(1):104\u2013113","journal-title":"J Immunol"},{"issue":"10","key":"11_CR6","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1038\/sj.leu.2404366","volume":"20","author":"A Loskog","year":"2006","unstructured":"Loskog A, Giandomenico V, Rossig C, Pule M, Dotti G, Brenner MK (2006) Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 20(10):1819\u20131828","journal-title":"Leukemia"},{"issue":"1","key":"11_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nbt0102-70","volume":"20","author":"J Maher","year":"2002","unstructured":"Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor. Nat Biotechnol 20(1):70\u201375","journal-title":"Nat Biotechnol"},{"issue":"5","key":"11_CR8","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G et al (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121(5):1822\u20131826","journal-title":"J Clin Invest"},{"issue":"1","key":"11_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1089\/hum.2009.122","volume":"21","author":"S Tammana","year":"2010","unstructured":"Tammana S, Huang X, Wong M, Milone MC, Ma L, Levine BL et al (2010) 4\u20131BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther 21(1):75\u201386","journal-title":"Hum Gene Ther"},{"issue":"8","key":"11_CR10","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1089\/hum.2007.028","volume":"18","author":"J Wang","year":"2007","unstructured":"Wang J, Jensen M, Lin Y, Sui X, Chen E, Lindgren CG et al (2007) Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther 18(8):712\u2013725","journal-title":"Hum Gene Ther"},{"key":"11_CR11","unstructured":"FDA Approval"},{"issue":"22","key":"11_CR12","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-14-1530","volume":"74","author":"SS Kenderian","year":"2014","unstructured":"Kenderian SS, Ruella M, Gill S, Kalos M (2014) Chimeric antigen receptor T-cell therapy to target hematologic malignancies. Cancer Res 74(22):6383\u20136389","journal-title":"Cancer Res"},{"issue":"3","key":"11_CR13","first-page":"190","volume":"12","author":"JN Kochenderfer","year":"2014","unstructured":"Kochenderfer JN (2014) Genetic engineering of T cells in leukemia and lymphoma. Clin Adv Hematol Oncol 12(3):190\u2013192","journal-title":"Clin Adv Hematol Oncol"},{"issue":"17","key":"11_CR14","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","volume":"123","author":"MV Maus","year":"2014","unstructured":"Maus MV, Grupp SA, Porter DL, June CH (2014) Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123(17):2625\u20132635","journal-title":"Blood"},{"issue":"4","key":"11_CR15","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Riviere I (2013) The basic principles of chimeric antigen receptor design. Cancer Discov 3(4):388\u2013398","journal-title":"Cancer Discov"},{"issue":"1","key":"11_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/imr.12243","volume":"263","author":"S Gill","year":"2015","unstructured":"Gill S, June CH (2015) Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev 263(1):68\u201389","journal-title":"Immunol Rev"},{"issue":"6","key":"11_CR17","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M et al (2016) CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 126(6):2123\u20132138","journal-title":"J Clin Invest"},{"issue":"15","key":"11_CR18","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","volume":"133","author":"KA Hay","year":"2019","unstructured":"Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D et al (2019) Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood 133(15):1652\u20131663","journal-title":"Blood"},{"key":"11_CR19","doi-asserted-by":"crossref","unstructured":"Turtle CJ, Hanafi LA, Berger C, Daniel Sommermeyer P, Barbara Pender MS, Emily M, Robinson BS, Melville K et al (2015) Addition of fludarabine to cyclophosphamide lymphodepletion improves in vivo expansion of CD19 chimeric antigen receptor-modified T cells and clinical outcome in adults with B cell acute lymphoblastic leukemia. Blood 126(23):3773","DOI":"10.1182\/blood.V126.23.3773.3773"},{"key":"11_CR20","doi-asserted-by":"crossref","unstructured":"Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF et al (2017) Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 7(12):1404\u20131419","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"11_CR21","doi-asserted-by":"publisher","first-page":"7024","DOI":"10.1200\/JCO.2017.35.15_suppl.7024","volume":"35","author":"JH Park","year":"2017","unstructured":"Park JH, Santomasso B, Riviere I, Senechal B, Wang X, Purdon T et al (2017) Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19\u201328z CAR T cells in adult patients with relapsed B-ALL. J Clin Oncol 35:7024","journal-title":"J Clin Oncol"},{"issue":"21","key":"11_CR22","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM et al (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130(21):2295\u20132306","journal-title":"Blood"},{"key":"11_CR23","doi-asserted-by":"crossref","unstructured":"Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG et al (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5(177):177ra38","DOI":"10.1126\/scitranslmed.3005930"},{"issue":"10","key":"11_CR24","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","volume":"34","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH et al (2016) Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol 34(10):1112\u20131121","journal-title":"J Clin Oncol"},{"issue":"17","key":"11_CR25","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","volume":"122","author":"CR Cruz","year":"2013","unstructured":"Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S et al (2013) Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 122(17):2965\u20132973","journal-title":"Blood"},{"key":"11_CR26","doi-asserted-by":"crossref","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K et al (2014) Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6(224):224ra25","DOI":"10.1126\/scitranslmed.3008226"},{"issue":"16","key":"11_CR27","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR et al (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368(16):1509\u20131518","journal-title":"N Engl J Med"},{"key":"11_CR28","doi-asserted-by":"crossref","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA et al (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385(9967):517\u2013528","DOI":"10.1016\/S0140-6736(14)61403-3"},{"issue":"5","key":"11_CR29","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ et al (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378(5):449\u2013459","journal-title":"N Engl J Med"},{"issue":"5","key":"11_CR30","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H et al (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378(5):439\u2013448","journal-title":"N Engl J Med"},{"issue":"23","key":"11_CR31","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1182\/blood.V126.23.3774.3774","volume":"126","author":"L Dong","year":"2015","unstructured":"Dong L, Chang LJ, Zhiyong G, Lu DP, Zhang JP, Wang JB et al (2015) Chimeric antigen receptor 4SCAR19-modified T cells in acute lymphoid leukemia: a phase II multi-center clinical trial in China. Blood 126(23):3774","journal-title":"Blood"},{"issue":"16","key":"11_CR32","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371(16):1507\u20131517","journal-title":"N Engl J Med"},{"issue":"23","key":"11_CR33","doi-asserted-by":"publisher","first-page":"3769","DOI":"10.1182\/blood.V126.23.3769.3769","volume":"126","author":"SR Rheingold","year":"2015","unstructured":"Rheingold SR, Chen LL, Maude SL, Aplenc R, Barker C, Barrett DM et al (2015) Efficient trafficking of chimeric antigen receptor (CAR)-modified T cells to CSF and induction of durable CNS remissions in children with CNS\/combined relapsed\/refractory ALL. Blood 126(23):3769","journal-title":"Blood"},{"issue":"12","key":"11_CR34","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/ajh.25274","volume":"93","author":"E Jacoby","year":"2018","unstructured":"Jacoby E, Bielorai B, Avigdor A, Itzhaki O, Hutt D, Nussboim V et al (2018) Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia. Am J Hematol 93(12):1485\u20131492","journal-title":"Am J Hematol"},{"key":"11_CR35","doi-asserted-by":"crossref","unstructured":"Zhang H, Hu Y, Wei G, Wu W, Huang H (2019) Successful chimeric antigen receptor T cells therapy in extramedullary relapses of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant","DOI":"10.1038\/s41409-019-0778-8"},{"key":"11_CR36","doi-asserted-by":"publisher","first-page":"6327","DOI":"10.2147\/OTT.S164430","volume":"11","author":"D Wang","year":"2018","unstructured":"Wang D, Shi R, Wang Q, Li J (2018) Extramedullary relapse of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation treated by CAR T-cell therapy: a case report. Onco Targets Ther 11:6327\u20136332","journal-title":"Onco Targets Ther"},{"issue":"4","key":"11_CR37","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25(4):625\u2013638","journal-title":"Biol Blood Marrow Transplant"},{"key":"11_CR38","doi-asserted-by":"crossref","unstructured":"Chang LJ, Dong L, Liu YC, Tsao ST, Li YC, Liu L et al (2016) Safety and efficacy evaluation of 4SCAR19 chimeric antigen receptor-modified T cells targeting B cell acute lymphoblastic leukemia\u2014three-year follow-up of a multicenter phase I\/II study. Blood 128(22):587","DOI":"10.1182\/blood.V128.22.587.587"},{"issue":"12","key":"11_CR39","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1038\/leu.2017.145","volume":"31","author":"J Pan","year":"2017","unstructured":"Pan J, Yang JF, Deng BP, Zhao XJ, Zhang X, Lin YH et al (2017) High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Leukemia 31(12):2587\u20132593","journal-title":"Leukemia"},{"key":"11_CR40","unstructured":"National Cancer Institute. Common terminology criteria for adverse events v4.3 (CTCAE)"},{"key":"11_CR41","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version 5.0"},{"issue":"2","key":"11_CR42","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124(2):188\u2013195","journal-title":"Blood"},{"issue":"1","key":"11_CR43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL et al (2018) Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nat Rev Clin Oncol 15(1):47\u201362","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"11_CR44","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","volume":"11","author":"D Porter","year":"2018","unstructured":"Porter D, Frey N, Wood PA, Weng Y, Grupp SA (2018) Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol 11(1):35","journal-title":"J Hematol Oncol"},{"issue":"9","key":"11_CR45","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/s41419-018-0918-x","volume":"9","author":"A Titov","year":"2018","unstructured":"Titov A, Petukhov A, Staliarova A, Motorin D, Bulatov E, Shuvalov O et al (2018) The biological basis and clinical symptoms of CAR-T therapy-associated toxicites. Cell Death Dis 9(9):897","journal-title":"Cell Death Dis"},{"issue":"6","key":"11_CR46","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N et al (2016) Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 6(6):664\u2013679","journal-title":"Cancer Discov"},{"key":"11_CR47","doi-asserted-by":"crossref","unstructured":"Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW et al (2015) Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 7(303):303ra139","DOI":"10.1126\/scitranslmed.aac5415"},{"key":"11_CR48","doi-asserted-by":"crossref","unstructured":"Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A et al (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3(95):95ra73","DOI":"10.1126\/scitranslmed.3002842"},{"key":"11_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2016.03.005","volume":"434","author":"F Chen","year":"2016","unstructured":"Chen F, Teachey DT, Pequignot E, Frey N, Porter D, Maude SL et al (2016) Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and\/or siltuximab following CAR T cell therapy. J Immunol Methods 434:1\u20138","journal-title":"J Immunol Methods"},{"issue":"1","key":"11_CR50","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-016-0299-5","volume":"9","author":"Y Hu","year":"2016","unstructured":"Hu Y, Sun J, Wu Z, Yu J, Cui Q, Pu C et al (2016) Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. J Hematol Oncol 9(1):70","journal-title":"J Hematol Oncol"},{"issue":"8","key":"11_CR51","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMc1704610","volume":"377","author":"JS Abramson","year":"2017","unstructured":"Abramson JS, McGree B, Noyes S, Plummer S, Wong C, Chen YB et al (2017) Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. N Engl J Med 377(8):783\u2013784","journal-title":"N Engl J Med"},{"issue":"11","key":"11_CR52","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.pt.2006.09.002","volume":"22","author":"HC van der Heyde","year":"2006","unstructured":"van der Heyde HC, Nolan J, Combes V, Gramaglia I, Grau GE (2006) A unified hypothesis for the genesis of cerebral malaria: sequestration, inflammation and hemostasis leading to microcirculatory dysfunction. Trends Parasitol 22(11):503\u2013508","journal-title":"Trends Parasitol"},{"issue":"14","key":"11_CR53","doi-asserted-by":"publisher","first-page":"5572","DOI":"10.1073\/pnas.86.14.5572","volume":"86","author":"GE Grau","year":"1989","unstructured":"Grau GE, Heremans H, Piguet PF, Pointaire P, Lambert PH, Billiau A et al (1989) Monoclonal antibody against interferon gamma can prevent experimental cerebral malaria and its associated overproduction of tumor necrosis factor. Proc Natl Acad Sci U S A 86(14):5572\u20135574","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11_CR54","doi-asserted-by":"crossref","unstructured":"Danylesko I, Chowers G, Shouval R, Besser MJ, Jacoby E, Shimoni A et al (2019) Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia. Curr Res Transl Med","DOI":"10.1016\/j.retram.2019.12.001"},{"key":"11_CR55","doi-asserted-by":"crossref","unstructured":"Jacoby E (2019) The role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemia. Bone Marrow Transplant 54(Suppl 2):810\u2013814","DOI":"10.1038\/s41409-019-0604-3"},{"issue":"2","key":"11_CR56","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.bbmt.2016.09.002","volume":"23","author":"SS Kenderian","year":"2017","unstructured":"Kenderian SS, Porter DL, Gill S (2017) Chimeric antigen receptor T cells and hematopoietic cell transplantation: how not to put the CART before the horse. Biol Blood Marrow Transplant 23(2):235\u2013246","journal-title":"Biol Blood Marrow Transplant"},{"key":"11_CR57","doi-asserted-by":"crossref","unstructured":"Grupp SA, Maude SL, Shaw PA, Aplenc R, Barrett DM, Callahan C et al (2015) Durable remissions in children with relapsed\/refractory ALL treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019). Blood 126(23):681","DOI":"10.1182\/blood.V126.23.681.681"},{"issue":"3","key":"11_CR58","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","volume":"109","author":"AK Fielding","year":"2007","unstructured":"Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G et al (2007) Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study. Blood 109(3):944\u2013950","journal-title":"Blood"},{"issue":"3","key":"11_CR59","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","volume":"75","author":"MM Horowitz","year":"1990","unstructured":"Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75(3):555\u2013562","journal-title":"Blood"},{"issue":"13","key":"11_CR60","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1182\/blood-2013-10-534297","volume":"123","author":"MA Pulsipher","year":"2014","unstructured":"Pulsipher MA, Langholz B, Wall DA, Schultz KR, Bunin N, Carroll WL et al (2014) The addition of sirolimus to tacrolimus\/methotrexate GVHD prophylaxis in children with ALL: a phase 3 children\u2019s oncology group\/pediatric blood and marrow transplant consortium trial. Blood 123(13):2017\u20132025","journal-title":"Blood"},{"issue":"3","key":"11_CR61","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","volume":"27","author":"P Bader","year":"2009","unstructured":"Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A et al (2009) Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM study group. J Clin Oncol 27(3):377\u2013384","journal-title":"J Clin Oncol"},{"issue":"25","key":"11_CR62","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K et al (2017) Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129(25):3322\u20133331","journal-title":"Blood"},{"issue":"6","key":"11_CR63","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M et al (2015) 4\u20131BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21(6):581\u2013590","journal-title":"Nat Med"},{"issue":"8","key":"11_CR64","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/mt.2009.83","volume":"17","author":"MC Milone","year":"2009","unstructured":"Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D et al (2009) Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 17(8):1453\u20131464","journal-title":"Mol Ther"},{"issue":"12","key":"11_CR65","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/s41408-017-0023-x","volume":"7","author":"E Mejstrikova","year":"2017","unstructured":"Mejstrikova E, Hrusak O, Borowitz MJ, Whitlock JA, Brethon B, Trippett TM et al (2017) CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment. Blood Cancer J 7(12):659","journal-title":"Blood Cancer J"},{"issue":"12","key":"11_CR66","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G et al (2015) Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 5(12):1282\u20131295","journal-title":"Cancer Discov"},{"issue":"5","key":"11_CR67","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/CJI.0000000000000169","volume":"40","author":"J Fischer","year":"2017","unstructured":"Fischer J, Paret C, El Malki K, Alt F, Wingerter A, Neu MA et al (2017) CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis. J Immunother 40(5):187\u2013195","journal-title":"J Immunother"},{"key":"11_CR68","doi-asserted-by":"publisher","first-page":"12320","DOI":"10.1038\/ncomms12320","volume":"7","author":"E Jacoby","year":"2016","unstructured":"Jacoby E, Nguyen SM, Fountaine TJ, Welp K, Gryder B, Qin H et al (2016) CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat Commun 7:12320","journal-title":"Nat Commun"},{"issue":"20","key":"11_CR69","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner R, Wu D, Cherian S, Fang M, Hanafi LA, Finney O et al (2016) Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127(20):2406\u20132410","journal-title":"Blood"},{"issue":"5906","key":"11_CR70","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1126\/science.1164266","volume":"322","author":"CG Mullighan","year":"2008","unstructured":"Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, Shurtleff SA et al (2008) Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322(5906):1377\u20131380","journal-title":"Science"},{"issue":"6","key":"11_CR71","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/pbc.25953","volume":"63","author":"A Rayes","year":"2016","unstructured":"Rayes A, McMasters RL, O\u2019Brien MM (2016) Lineage Switch in MLL-Rearranged infant leukemia following CD19-directed therapy. Pediatr Blood Cancer 63(6):1113\u20131115","journal-title":"Pediatr Blood Cancer"},{"issue":"18","key":"11_CR72","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1182\/blood-2017-05-782888","volume":"130","author":"I Nagel","year":"2017","unstructured":"Nagel I, Bartels M, Duell J, Oberg HH, Ussat S, Bruckmueller H et al (2017) Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy. Blood 130(18):2027\u20132031","journal-title":"Blood"},{"key":"11_CR73","doi-asserted-by":"crossref","unstructured":"Oberley MJ, Gaynon PS, Bhojwani D, Pulsipher MA, Gardner RA, Hiemenz MC et al (2018) Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia. Pediatr Blood Cancer 65(9):e27265","DOI":"10.1002\/pbc.27265"},{"key":"11_CR74","doi-asserted-by":"crossref","unstructured":"Lee DW, Stetler-Stevenson M, Yuan C, Shah NN, Delbrook C, Yates B et al (2016) Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine\/cyclophosphamide preparative regimen and post-car hematopoietic stem cell transplantation. Blood 128(22):218","DOI":"10.1182\/blood.V128.22.218.218"},{"key":"11_CR75","doi-asserted-by":"crossref","unstructured":"Zhang Y, Chen H, Song Y, Tan X, Zhao Y, Liu X et al (2019) Post-chimeric antigen receptor T-cell therapy haematopoietic stem cell transplantation for 52 cases with refractory\/relapsed B-cell acute lymphoblastic leukaemia. Br J Haematol","DOI":"10.1111\/bjh.16339"}],"container-title":["Cancer Treatment and Research","Biology and Treatment of Leukemia and Bone Marrow Neoplasms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-78311-2_11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T14:59:25Z","timestamp":1633877965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-78311-2_11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783030783105","9783030783112"],"references-count":75,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-78311-2_11","relation":{},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"type":"print","value":"0927-3042"},{"type":"electronic","value":"2509-8497"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"10 October 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}